These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

820 related articles for article (PubMed ID: 22184378)

  • 21. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Izutsu K; Yamamoto K; Kato K; Ishikawa T; Fukuhara N; Terui Y; Choi I; Humphrey K; Kim SY; Okubo S; Ogawa N; Nishimura Y; Salem AH; Maruyama D
    Int J Hematol; 2021 Mar; 113(3):370-380. PubMed ID: 33094474
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells.
    Sharma A; Singh K; Mazumder S; Hill BT; Kalaycio M; Almasan A
    Cell Death Dis; 2013 May; 4(5):e628. PubMed ID: 23681223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199.
    Khaw SL; Mérino D; Anderson MA; Glaser SP; Bouillet P; Roberts AW; Huang DC
    Leukemia; 2014 Jun; 28(6):1207-15. PubMed ID: 24402163
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The putative BH3 mimetic S1 sensitizes leukemia to ABT-737 by increasing reactive oxygen species, inducing endoplasmic reticulum stress, and upregulating the BH3-only protein NOXA.
    Soderquist R; Pletnev AA; Danilov AV; Eastman A
    Apoptosis; 2014 Jan; 19(1):201-9. PubMed ID: 24072590
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors.
    Cleary JM; Lima CM; Hurwitz HI; Montero AJ; Franklin C; Yang J; Graham A; Busman T; Mabry M; Holen K; Shapiro GI; Uronis H
    Invest New Drugs; 2014 Oct; 32(5):937-45. PubMed ID: 24916770
    [TBL] [Abstract][Full Text] [Related]  

  • 26. From mitochondrial biology to magic bullet: navitoclax disarms BCL-2 in chronic lymphocytic leukemia.
    Walensky LD
    J Clin Oncol; 2012 Feb; 30(5):554-7. PubMed ID: 22184389
    [No Abstract]   [Full Text] [Related]  

  • 27. Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies.
    King AC; Peterson TJ; Horvat TZ; Rodriguez M; Tang LA
    Ann Pharmacother; 2017 May; 51(5):410-416. PubMed ID: 28056525
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.
    Gandhi L; Camidge DR; Ribeiro de Oliveira M; Bonomi P; Gandara D; Khaira D; Hann CL; McKeegan EM; Litvinovich E; Hemken PM; Dive C; Enschede SH; Nolan C; Chiu YL; Busman T; Xiong H; Krivoshik AP; Humerickhouse R; Shapiro GI; Rudin CM
    J Clin Oncol; 2011 Mar; 29(7):909-16. PubMed ID: 21282543
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
    Stilgenbauer S; Eichhorst B; Schetelig J; Coutre S; Seymour JF; Munir T; Puvvada SD; Wendtner CM; Roberts AW; Jurczak W; Mulligan SP; Böttcher S; Mobasher M; Zhu M; Desai M; Chyla B; Verdugo M; Enschede SH; Cerri E; Humerickhouse R; Gordon G; Hallek M; Wierda WG
    Lancet Oncol; 2016 Jun; 17(6):768-778. PubMed ID: 27178240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The BH3-only protein Puma plays an essential role in p53-mediated apoptosis of chronic lymphocytic leukemia cells.
    Zhu HJ; Liu L; Fan L; Zhang LN; Fang C; Zou ZJ; Li JY; Xu W
    Leuk Lymphoma; 2013 Dec; 54(12):2712-9. PubMed ID: 23517560
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progress in BCL2 inhibition for patients with chronic lymphocytic leukemia.
    Tam CS; Seymour JF; Roberts AW
    Semin Oncol; 2016 Apr; 43(2):274-9. PubMed ID: 27040706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Phase I study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumors.
    Puglisi M; Molife LR; de Jonge MJ; Khan KH; Doorn LV; Forster MD; Blanco M; Gutierrez M; Franklin C; Busman T; Yang J; Eskens FA
    Future Oncol; 2021 Jul; 17(21):2747-2758. PubMed ID: 33849298
    [No Abstract]   [Full Text] [Related]  

  • 33. The first MCL-1-selective BH3 mimetics have therapeutic potential for chronic lymphocytic leukemia.
    Besbes S; Pocard M; Mirshahi M; Billard C
    Crit Rev Oncol Hematol; 2016 Apr; 100():32-6. PubMed ID: 26899021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo.
    Chen J; Jin S; Abraham V; Huang X; Liu B; Mitten MJ; Nimmer P; Lin X; Smith M; Shen Y; Shoemaker AR; Tahir SK; Zhang H; Ackler SL; Rosenberg SH; Maecker H; Sampath D; Leverson JD; Tse C; Elmore SW
    Mol Cancer Ther; 2011 Dec; 10(12):2340-9. PubMed ID: 21914853
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma.
    Tanos R; Karmali D; Nalluri S; Goldsmith KC
    BMC Cancer; 2016 Feb; 16():97. PubMed ID: 26874859
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted therapy for chronic lymphocytic leukemia: a glimpse into the future.
    Hillmen P
    J Clin Oncol; 2012 Feb; 30(5):469-70. PubMed ID: 22184387
    [No Abstract]   [Full Text] [Related]  

  • 37. Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia.
    Roberts AW; Stilgenbauer S; Seymour JF; Huang DCS
    Clin Cancer Res; 2017 Aug; 23(16):4527-4533. PubMed ID: 28100580
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
    Pullarkat VA; Lacayo NJ; Jabbour E; Rubnitz JE; Bajel A; Laetsch TW; Leonard J; Colace SI; Khaw SL; Fleming SA; Mattison RJ; Norris R; Opferman JT; Roberts KG; Zhao Y; Qu C; Badawi M; Schmidt M; Tong B; Pesko JC; Sun Y; Ross JA; Vishwamitra D; Rosenwinkel L; Kim SY; Jacobson A; Mullighan CG; Alexander TB; Stock W
    Cancer Discov; 2021 Jun; 11(6):1440-1453. PubMed ID: 33593877
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: an ex vivo experiment in human serous ovarian carcinoma.
    Lheureux S; N'Diaye M; Blanc-Fournier C; Dugué AE; Clarisse B; Dutoit S; Giffard F; Abeilard E; Briand M; Labiche A; Grellard JM; Crouet H; Martin S; Joly F; Poulain L
    Int J Cancer; 2015 Mar; 136(5):E340-50. PubMed ID: 25066666
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bcl-2 antagonists: a proof of concept for CLL therapy.
    Balakrishnan K; Gandhi V
    Invest New Drugs; 2013 Oct; 31(5):1384-94. PubMed ID: 23907405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.